ATS 2020 Advance Program

9:35 USPSTF Update M. Barry, MD, Boston, MA 9:55 NELSON Update H.J. de Koning, MD, PhD, Rotterdam, Netherlands 10:15 CMS Decision Making: An In/Outsider’s Perspective M.K. Gould, MD, MS, Pasadena, CA 10:35 Radiomics and Risk Prediction Models: What Do We Have and What Have Others Done? C.R. Sears, MD, ATSF, Indianapolis, IN 10:55 Why Is No One Doing It and What (If Anything) Should Be Done About It? Speaker To Be Announced BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM B8 INFLAMMATION IN ARDS: TOO MUCH OR TOO LITTLE? Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Pediatrics; Respiratory Cell and Molecular Biology 9:15 a.m. - 11:15 a.m. Target Audience Basic research scientists, Translational researchers, pulmonary biologists, critical care Objectives At the conclusion of this session, the participant will be able to: • understand the current evidence for high risk phenotypes of ARDS and the evidence for immunologic underpinnings for these phenotypes; • learn current immunologic mechanisms such as programmed cell death and autophagy that, when dysregulated, may identify a high-risk subset of ARDS; • understand the concept of immune exhaustion and the inflammation arc over the course of critical illness. This symposium focuses on emerging understanding of the biology of inflammation in ARDS. Evidence suggests that subsets of ARDS patients with high levels of inflammation are both at increased risk for bad outcomes and may experience differential response to therapy. However, a later anti-inflammatory response, particularly in sepsis-induced ARDS, can produce immune ‘exhaustion’ which is also associated with adverse outcomes. It has been speculated that ‘reviving’ the inflammatory response later in the course of critical illness might prove beneficial, though this approach is fraught with potential complications, including the uncertain time course of inflammation in an individual patient and an ‘auto-immune’ exuberant inflammatory response that might paradoxically promote additional lung injury. There will be 5 minutes of discussion after each speaker. Chairing: A. Rogers, MPH, MD, Stanford, CA R.M. Baron, MD, Boston, MA J. Bhattacharya, MD, New York, NY 9:15 Introduction: Heterogeneity in ARDS: A Need for Improved Understanding of the Biologic Underpinnings R.M. Baron, MD, Boston, MA 9:35 What We Know About Immune Checkpoints in ARDS C. Mikacenic, MD, Seattle, WA 9:55 Neutrophil Priming in ARDS C. Summers, MBBS, PhD, Cambridge, United Kingdom 10:15 Targeting Inflammation in ARDS: The Right Time and Place B.D. Levy, MD, ATSF, Boston, MA 10:35 Does Inflammation in Peripheral Blood Reflect the Injured Lung in ARDS? A. Rogers, MPH, MD, Stanford, CA 10:55 Exosomes and Extracellular Vesicles in ARDS: Local Inflammatory Mediators M.A. Matthay, MD, San Francisco, CA ATS 2020 • Philadelphia, PA MONDAY • MAY 18 71